Synthetic CRISPR RNA-Cas9-guided Genome editing in human cells

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 51, 2015, Pages E71110-E71117

  Rahdar, Meghdad ^a   McMahon, Moira A ^b   Prakash, Thazha P ^a   Swayze, Eric E ^a   Bennett, C Frank ^a   Cleveland, Don W ^b  

^a ISIS PHARMACEUTICALS   (United States)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (United States)

Author keywords

CRISPR Cas9; Genome editing; ScrRNA; Synthetic crRNA

Indexed keywords

CRISPR ASSOCIATED PROTEIN; GUIDE RNA; RNA; SYNTHETIC DNA;

ARTICLE; CHEMICAL MODIFICATION; COMPARATIVE STUDY; CRISPR CAS SYSTEM; GENE DISRUPTION; GENETIC PROCEDURES; GENETIC TRANSFECTION; GENOME EDITING; HUMAN; HUMAN CELL; INTERACTIONS WITH RNA; PRIORITY JOURNAL; RNA HYBRIDIZATION; RNA STABILITY; RNA SYNTHESIS; TRANSACTIVATION; BIOLOGICAL MODEL; CHEMISTRY; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; CONFORMATION; GENETIC ENGINEERING; GENETICS; HEK293 CELL LINE; HUMAN GENOME; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; RNA EDITING;

BASE SEQUENCE; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS; GENES, SYNTHETIC; GENETIC ENGINEERING; GENOME, HUMAN; HEK293 CELLS; HUMANS; MODELS, GENETIC; MOLECULAR SEQUENCE DATA; NUCLEIC ACID CONFORMATION; RNA; RNA EDITING; RNA, GUIDE;

EID: 84952701157     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1520883112     Document Type: Article

References (52)

1. Wiedenheft B, Sternberg SH, Doudna JA (2012) RNA-guided genetic silencing systems in bacteria and archaea. Nature 482(7385):331-338.
2. Bhaya D, Davison M, Barrangou R (2011) CRISPR-Cas systems in bacteria and archaea: Versatile small RNAs for adaptive defense and regulation. Annu Rev Genet 45:273-297.
3. Terns MP, Terns RM (2011) CRISPR-based adaptive immune systems. Curr Opin Microbiol 14(3):321-327.
4. Makarova KS, et al. (2011) Evolution and classification of the CRISPR-Cas systems. Nat Rev Microbiol 9(6):467-477.
5. Barrangou R, et al. (2007) CRISPR provides acquired resistance against viruses in prokaryotes. Science 315(5819):1709-1712.
6. Jinek M, et al. (2012) A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337(6096):816-821.
7. Cong L, et al. (2013) Multiplex genome engineering using CRISPR/Cas systems. Science 339(6121):819-823.
8. Mali P, et al. (2013) RNA-guided human genome engineering via Cas9. Science 339(6121):823-826.
9. Carroll D (2014) Genome engineering with targetable nucleases. Annu Rev Biochem 83:409-439.
10. McMahon MA, Rahdar M, Porteus M (2012) Gene editing: Not just for translation anymore. Nat Methods 9(1):28-31.
11. Hsu PD, Lander ES, Zhang F (2014) Development and applications of CRISPR-Cas9 for genome engineering. Cell 157(6):1262-1278.
12. Sternberg SH, Doudna JA (2015) Expanding the Biologist's Toolkit with CRISPR-Cas9. Mol Cell 58(4):568-574.
13. Wen J, et al. (2014) Xylose phosphorylation functions as a molecular switch to regulate proteoglycan biosynthesis. Proc Natl Acad Sci USA 111(44):15723-15728.
14. Fachinetti D, et al. (2015) DNA sequence-specific binding of CENP-B enhances the fidelity of human centromere function. Dev Cell 33(3):314-327.
15. Wang H, et al. (2013) One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell 153(4):910-918.
16. Li D, et al. (2013) Heritable gene targeting in the mouse and rat using a CRISPR-Cas system. Nat Biotechnol 31(8):681-683.
17. Ran FA, et al. (2015) In vivo genome editing using Staphylococcus aureus Cas9. Nature 520(7546):186-191.
18. Platt RJ, et al. (2014) CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell 159(2):440-455.
19. Chen S, et al. (2015) Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis. Cell 160(6):1246-1260.
20. Cox DBT, Platt RJ, Zhang F (2015) Therapeutic genome editing: Prospects and challenges. Nat Med 21(2):121-131.
21. Baltimore D, et al. (2015) Biotechnology. A prudent path forward for genomic engineering and germline gene modification. Science 348(6230):36-38.
22. Hendel A, et al. (2015) Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. Nat Biotechnol 33(9):985-989.
23. Fu Y, et al. (2013) High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol 31(9):822-826.
24. Hsu PD, et al. (2013) DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol 31(9):827-832.
25. Pattanayak V, et al. (2013) High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. Nat Biotechnol 31(9):839-843.
26. Kuscu C, Arslan S, Singh R, Thorpe J, Adli M (2014) Genome-wide analysis reveals characteristics of off-target sites bound by the Cas9 endonuclease. Nat Biotechnol 32(7):677-683.
27. Tsai SQ, et al. (2015) GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat Biotechnol 33(2):187-197.
28. Lin S, Staahl BT, Alla RK, Doudna JA (2014) Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery. eLife 3:e04766.
29. Braasch DA, et al. (2003) RNA interference in mammalian cells by chemically-modified RNA. Biochemistry 42(26):7967-7975.
30. Chiu Y-L, Rana TM (2003) siRNA function in RNAi: A chemical modification analysis. RNA 9(9):1034-1048.
31. Eckstein F (2014) Phosphorothioates, essential components of therapeutic oligonucleotides. Nucleic Acid Ther 24(6):374-387.
32. Qiu P, et al. (2004) Mutation detection using Surveyor nuclease. Biotechniques 36(4):702-707.
33. Bennett CF, Swayze EE (2010) RNA targeting therapeutics: Molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 50:259-293.
34. Seth PP, et al. (2010) Synthesis and biophysical evaluation of 2', 4'-constrained 2'O-methoxyethyl and 2', 4'-constrained 2'O-ethyl nucleic acid analogues. J Org Chem 75(5):1569-1581.
35. Jiang F, Zhou K, Ma L, Gressel S, Doudna JA (2015) STRUCTURAL BIOLOGY. A Cas9-guide RNA complex preorganized for target DNA recognition. Science 348(6242):1477-1481.
36. Fu Y, Sander JD, Reyon D, Cascio VM, Joung JK (2014) Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat Biotechnol 32(3):279-284.
37. Dellinger DJ, Sheehan DM, Christensen NK, Lindberg JG, Caruthers MH (2003) Solidphase chemical synthesis of phosphonoacetate and thiophosphonoacetate oligodeoxynucleotides. J Am Chem Soc 125(4):940-950.
38. Soutschek J, et al. (2004) Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432(7014):173-178.
39. Smith RA, et al. (2006) Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest 116(8):2290-2296.
40. Passini MA, et al. (2011) Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci Transl Med 3(72):72ra18.
41. Yu D, et al. (2012) Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression. Cell 150(5):895-908.
42. Koller E, et al. (2011) Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes. Nucleic Acids Res 39(11):4795-4807.
43. Burnett JC, Rossi JJ (2012) RNA-based therapeutics: Current progress and future prospects. Chem Biol 19(1):60-71.
44. Agrawal S, Kandimalla ER (2004) Antisense and siRNA as agonists of Toll-like receptors. Nat Biotechnol 22(12):1533-1537.
45. Zincarelli C, Soltys S, Rengo G, Rabinowitz JE (2008) Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther 16(6):1073-1080.
46. Mingozzi F, High KA (2011) Therapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges. Nat Rev Genet 12(5):341-355.
47. Foust KD, et al. (2013) Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS. Mol Ther 21(12):2148-2159.
48. Hua Y, et al. (2015) Motor neuron cell-nonautonomous rescue of spinal muscular atrophy phenotypes in mild and severe transgenic mouse models. Genes Dev 29(3):288-297.
49. Gilbert LA, et al. (2014) Genome-scale CRISPR-mediated control of gene repression and activation. Cell 159(3):647-661.
50. Chen B, et al. (2013) Dynamic imaging of genomic loci in living human cells by an optimized CRISPR/Cas system. Cell 155(7):1479-1491.
51. Tanenbaum ME, Gilbert LA, Qi LS, Weissman JS, Vale RD (2014) A protein-tagging system for signal amplification in gene expression and fluorescence imaging. Cell 159(3):635-646.
52. Prakash TP, et al. (2005) Positional effect of chemical modifications on short interference RNA activity in mammalian cells. J Med Chem 48(13):4247-4253.